Marginal resection of solitary plasmacytoma in the anterior region of the mandible and dental implant rehabilitation: Report of an unusual case
ConclusionThe patient is currently undergoing clinical and radiological follow-up of 2 years with sucess.
Publication date: Available online 19 October 2019Source: Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)Author(s): C. Perrilla-Rodrigo, O.M. Urrego-Meléndez
Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10, SupplementAuthor(s): Shotaro Chinen, Dai Maruyama, Akiko Miyagi Maeshima, Kinuko Tajima, Yo Saito, Takahiro Fujino, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Koji Izutsu
CONCLUSIONS PVT1 exerts an oncogenic role through activating Wnt/ß-catenin signaling in pituitary adenoma cells. The present results may provide a potential therapeutic target or approach for treating pituitary adenomas. PMID: 31604907 [PubMed - in process]
PMID: 31610880 [PubMed - as supplied by publisher]
Primary mediastinal non-Hodgkin lymphomas (PM-NHLs) represent ∼5% of all non-Hodgkin lymphomas (NHLs) and comprise lymphomas of B-cell and T-cell origin. PM-NHLs are defined as involvement of mediastinal lymph nodes, thymus, and/or mediastinal organs (heart, lung, pleura, pericardium) by NHL without evidence of systemic disease at presentation. The clinical scenario is variable and depends on the lymphoma subtype. The radiologic presentation is also variable ranging from a mediastinal mass with or without superior vena cava syndrome, a pleural or a cardiac mass associated with effusion, or as an effusion only. The diag...
Authors: Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R Abstract The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. T...
This case report describes a patient in their 30s who presented with sudden onset of 3 generalized tonic-clonic seizures, double vision, and several days of headache, and was diagnosed with a skull base and orbital solitary plasmacytoma.
We present data showing improvement in response on treatment and in survival in Swedish MM patients since the forming of the national Swedish Myeloma Registry (SMR).
As per the International Myeloma Working Group (IMWG) 2016 criteria, response evaluation in multiple myeloma takes into consideration two main components: clinical data (e.g., SPEP, UPEP, Immunofixation, etc.) and imaging-based plasmacytoma/ myeloma-lesions assessment. Independent central review of imaging and clinical data may be required for clinical trial submission. Currently, no clear guidance is available on acceptable imaging modalities and various types of myeloma lesions seen on imaging.
Solitary plasmacytoma (SPC) is an infrequent form of plasma cell (PC) dyscrasia that presents as a single mass of monoclonal PCs, either extramedullary or intraosseous, with limited (